Dr. G interviews Emmy winning journalist Kym Nicholas, CEO and co‑founder of the Global PAD Association, about peripheral arterial disease (PAD), its strong link to diabetes, common misdiagnoses, and why early vascular evaluation can prevent unnecessary amputations.

They discuss patient stories, systemic gaps in care, lifestyle interventions like supervised walking programs, global best practices, and resources to get help at padhelp.org.

In this episode of Diabetic Foot Files, Dr. G explores how existing medications — from metformin and insulin to statins, fentanyl, sildenafil, doxycycline and nitric oxide donors — are being repurposed to help heal stubborn diabetic foot ulcers. We review the biology behind each drug, early clinical evidence, and why topical formulations may offer targeted benefits with minimal systemic exposure.

Listeners will learn which agents show the strongest signals (topical insulin, topical metformin, topical statins), which remain promising but mixed (topical phenytoin), and how repurposed therapies fit as adjuncts to standard wound care rather than replacements. Practical takeaways include safety considerations, off-label use discussions, and the need for larger trials.

This episode explores new randomized evidence that semaglutide, a GLP-1 receptor agonist used for diabetes and weight loss, can improve walking distance and quality of life for people with type 2 diabetes and symptomatic peripheral arterial disease (PAD).

The landmark STRID trial showed median gains of about 26 meters (mean ~40 m) in walking distance over a year, along with better pain scores and daily function. Large real-world studies also suggest fewer PAD-related hospitalizations and amputations.

Benefits likely come from multiple effects: weight loss and improved glucose control, anti-inflammatory actions, better endothelial function and muscle metabolism, all combining to improve perfusion and exercise capacity.

Semaglutide is an adjunct to standard PAD care (exercise, smoking cessation, statins, antiplatelets, revascularization when needed). Common side effects include GI symptoms; monitor eye health, pancreatitis risk, and avoid use in patients with MEN2 or medullary thyroid cancer history.

In this episode of Diabetic Food Files we explain how peripheral arterial disease (PAD) and chronic kidney disease (CKD) interact in people with diabetes to worsen circulation, slow wound healing, and raise the risk of infection and limb loss.

We outline the key symptoms to watch for, recommended screening tests (ABI/toe–brachial index, urine albumin-to-creatinine ratio, eGFR), and why every person with diabetes should be evaluated for both conditions.

Management strategies discussed include antiplatelet and lipid therapy, ACEi/ARBs, SGLT2/GLP-1 agents, supervised exercise, diligent foot care, revascularization when needed, and close coordination among nephrology, vascular, podiatry, and endocrinology.

Early detection, aggressive risk control, and a multidisciplinary care team can greatly reduce the chance of amputation and preserve kidney function—know the signs and get screened.

This episode of Diabetic Foot Files explores peripheral arterial disease (PAD) in people with diabetes — its history, how diabetes accelerates arterial damage, the biology behind impaired wound healing, and clinical clues to distinguish ischemic from neuropathic ulcers.

We cover bedside tests (ABI, TBI, TcPO2), modern revascularization options, medical and lifestyle management, and emerging therapies, emphasizing early recognition and multidisciplinary care to improve limb salvage and outcomes.

Dr. G explains how nicotine — from cigarettes, vapes, pouches, and nicotine replacement products — reduces blood flow, disrupts immune and cellular repair, and slows or worsens healing in diabetic foot wounds.

He summarizes the science, lists nicotine-containing products, and gives practical, evidence-based guidance for clinicians and patients on screening, cessation options, and wound-care strategies to improve outcomes while working toward nicotine abstinence.

A focused look at fifth metatarsal ulcers in diabetic patients — why they form, how the peroneus brevis and lateral biomechanics drive injury, and the clinical strategies to heal and prevent recurrence.

This episode explains Monckeberg ("Mockingbird") sclerosis—a medial arterial calcification common in diabetes and chronic kidney disease—how it stiffens arteries without narrowing the lumen, and why it can make ABI results falsely reassuring.

Learn how to spot the classic railroad-track calcifications on x-ray, which vascular tests to use instead (toe-brachial index, duplex ultrasound, TcPO2), and why multidisciplinary care and optimized medical management are essential.

The episode covers practical steps for diagnosis, monitoring, and treatment planning to prevent delayed care and improve limb salvage outcomes in diabetic foot patients.